Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SHL Telemedicine Ltd American Depositary Shares (SHLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SHLT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.4% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 39.26M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 0.29 | 52 Weeks Range 1.85 - 4.83 | Updated Date 07/11/2025 |
52 Weeks Range 1.85 - 4.83 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.8% | Operating Margin (TTM) -14.07% |
Management Effectiveness
Return on Assets (TTM) -4.07% | Return on Equity (TTM) -11.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38497073 | Price to Sales(TTM) 0.7 |
Enterprise Value 38497073 | Price to Sales(TTM) 0.7 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA 16.11 | Shares Outstanding 16391400 | Shares Floating 10360993 |
Shares Outstanding 16391400 | Shares Floating 10360993 | ||
Percent Insiders - | Percent Institutions 21.8 |
Upturn AI SWOT
SHL Telemedicine Ltd American Depositary Shares
Company Overview
History and Background
SHL Telemedicine Ltd. (American Depositary Shares) was founded in 1987. It is a global provider of telemedicine solutions, focusing on remote cardiac monitoring and other remote patient care services. They have evolved from initially providing emergency response services to offering comprehensive telemedicine platforms.
Core Business Areas
- Telecardiology: Remote cardiac monitoring services, including ECG transmission and analysis.
- Remote Patient Monitoring (RPM): Platforms and services for remotely monitoring patients with chronic conditions like heart failure and diabetes.
- Personal Emergency Response Systems (PERS): Solutions that allow elderly or disabled individuals to call for help in case of an emergency.
Leadership and Structure
Key leaders include the CEO and CFO. The organizational structure is likely a mix of functional departments (e.g., R&D, Sales, Marketing) and business units (e.g., Telecardiology, RPM).
Top Products and Market Share
Key Offerings
- MOMO Cardiac Monitoring System: A system for real-time ECG monitoring and analysis. Market share data is difficult to pinpoint precisely, but key competitors include companies like iRhythm Technologies (IRTC), BioTelemetry (part of Philips), and Preventice Solutions (part of Boston Scientific).
- RPM Platform: A platform for remotely monitoring patients with chronic conditions. Market share is fragmented. Competitors include Teladoc Health (TDOC), Amwell (AMWL), and many smaller telehealth providers.
Market Dynamics
Industry Overview
The telemedicine industry is experiencing rapid growth, driven by factors like aging populations, increasing chronic disease prevalence, and technological advancements.
Positioning
SHL Telemedicine is positioned as a provider of comprehensive telemedicine solutions, with a strong focus on cardiac monitoring. Their competitive advantages include their expertise in telecardiology and their established presence in certain markets.
Total Addressable Market (TAM)
The global telemedicine market is expected to reach hundreds of billions of USD. SHL Telemedicine is positioned to capture a share of this market through its specialized services.
Upturn SWOT Analysis
Strengths
- Established presence in the telecardiology market
- Comprehensive telemedicine platform
- Strong technology expertise
- Experienced management team
Weaknesses
- Smaller size compared to larger telehealth companies
- Limited brand recognition in some markets
- Dependence on reimbursement policies
Opportunities
- Expanding into new geographic markets
- Developing new telemedicine solutions
- Acquiring smaller telehealth companies
- Partnering with healthcare providers
Threats
- Increasing competition from larger telehealth companies
- Changes in reimbursement policies
- Technological obsolescence
- Data security breaches
Competitors and Market Share
Key Competitors
- TDOC
- AMWL
- IRTC
Competitive Landscape
SHL Telemedicine faces intense competition from larger, more established telehealth companies. Their ability to compete depends on their expertise in specific areas like telecardiology, their ability to innovate, and their effectiveness in marketing their solutions.
Major Acquisitions
CCM
- Year: 2020
- Acquisition Price (USD millions): 7.1
- Strategic Rationale: To expand its remote patient monitoring capabilities in the US market.
Growth Trajectory and Initiatives
Historical Growth: Growth trends are available in parent SHL Telemedicine Ltd.'s financial reports.
Future Projections: Future growth projections are typically based on analyst estimates. Consider using available financial data to analyze potential growth.
Recent Initiatives: Recent initiatives include expanding their RPM platform and developing new telemedicine solutions.
Summary
SHL Telemedicine holds a niche position in the telemedicine market, particularly in telecardiology. While it faces competition from larger players, its specialized expertise offers a competitive edge. The company needs to strategically expand its market presence and leverage technological advancements to drive future growth. Its reliance on reimbursement policies presents an ongoing risk to financial performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SHL Telemedicine Ltd.)
- Market Research Reports (Telemedicine Industry)
- Financial News Outlets
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share estimates are based on publicly available data and may not be precise. Always consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SHL Telemedicine Ltd American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-04-03 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 583 | Website https://www.shl-telemedicine.com |
Full time employees 583 | Website https://www.shl-telemedicine.com | ||
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.